METHODS FOR THE TREATMENT OF HRD CANCER AND BRCA-ASSOCIATED CANCER

Organization Name

Inventor(s)

METHODS FOR THE TREATMENT OF HRD CANCER AND BRCA-ASSOCIATED CANCER

This abstract first appeared for US patent application 20250019708 titled 'METHODS FOR THE TREATMENT OF HRD CANCER AND BRCA-ASSOCIATED CANCER

Original Abstract Submitted

the invention relates to methods and pharmaceutical compositions for the treatment of cancer, particularly brca-associated cancer and chemo-resistance brca-associated cancer. the inventors investigated the role of nmnat1 in cancer, particularly in brca-associated cancer. the inventors demonstrated that nmnat1 inhibition kills brca1 and brca2-mutated tumor cells but does not affect the survival of non-brca-mutated cells. the inventors also demonstrated that nmnat1, a nuclear enzyme other than parp1, is crucial for the survival of hrd cells and indicate that nmnat1 is a key factor which activities are necessary for the survival of hrd cells. the inventors also demonstrated that inhibition of nmnat1 kills parp-inhibitor and cisplatin-resistant brca1 and brca2-mutated tumors and show that targeting nmnat1 kills chemo-resistance hrd cells, particularly parpi-resistant hrd cells. altogether, the present invention highlights the role of nmnat1 inhibitors in cancer and the use of nmnat1 inhibitors in the treatment of cancer, particularly brca-associated cancer including brca-associated cancer with acquired drug resistance in mono- or combination therapy with parpi. in the present invention, the inventors provide in vitro evidences towards a direct role of nmnat1 in brca-associated cancer. thus, the present invention relates to nmnat1 inhibitor for use in the treatment of cancer, particularly hrd cancer. brca-associated cancer and chemo-resistance brca-associated cancer.